Colinz Laboratories Limited has filed an official disclosure with the Bombay Stock Exchange regarding the transmission of a significant shareholding following the demise of one of its promoters. The pharmaceutical company submitted the regulatory disclosure under Regulation 7(2)(a) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, along with Form C documentation.

Share Transmission Details

The transmission involves 8,67,750 equity shares, representing 34.45% of the company's paid-up equity share capital. These shares belonged to the late Dr. Mani L.S., who was a promoter of the company. Following his demise, the shares have been transmitted to his nominee Mrs. Vijaya Mani, who is also a member of the promoter and promoter group and the wife of the late Dr. Mani L.S.

Shareholding Pattern Changes

The transmission has resulted in a significant change in Mrs. Vijaya Mani's individual shareholding pattern. Her total holding has increased substantially following the inheritance of her late husband's shares, making her the largest individual shareholder in the company.

Regulatory Compliance Framework

The company has filed the disclosure in compliance with SEBI's Prohibition of Insider Trading Regulations, specifically under Regulation 7(2)(a). The submission includes Form C documentation detailing the acquisition of shares through transmission. The company emphasized that this acquisition has been effected through transmission of shares and there is no change in the overall promoter group shareholding.

Company Capital Structure

The company's equity share capital remains unchanged following the transmission. Colinz Laboratories operates in the pharmaceutical sector and is listed on the Bombay Stock Exchange with the code 531210.

The transmission maintains the same total holding of the promoter and promoter group both prior to and post the transmission, ensuring continuity in the company's ownership structure while complying with all regulatory requirements for substantial shareholding changes.

Colinz Laboratories Ltd has announced significant corporate developments following a board meeting held on November 27, 2025. The company has made two key decisions that could impact its operations and governance structure.

Authorization for Factory Premises Sale

The board of directors has granted authority to Mr. Narayan Kutty Menon, Whole-time Director and CEO, to identify potential buyers and negotiate terms for the proposed sale of the company's factory premises. This decision follows shareholder approval obtained through a postal ballot on November 17, 2025, under Section 180(1)(a) of the Companies Act, 2013.

New Company Secretary Appointment

In addition to the sale authorization, the board has approved the appointment of Ms. Falguni Kumawat as the new Company Secretary and Compliance Officer. This appointment will take effect from December 1, 2025.

Here's a summary of the key details:

The board meeting, which commenced at 3:30 p.m., concluded at 5:30 p.m.

These developments suggest that Colinz Laboratories is taking strategic steps towards potential restructuring with the proposed factory sale, while also strengthening its corporate governance with the appointment of an experienced Company Secretary.